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Nicotinic acetylcholine receptors (nAChRs) are involved in a familial form of frontal lobe epilepsy, autosomal
dominant nocturnal frontal lobe epilepsy (ADNFLE). In several ADNFLE families, mutations were identified in
the nAChR a4 or b2 subunit, which together compose the main cerebral nAChR. Electrophysiological assess-
ment using in vitro expression systems indicated a gain of function of themutant receptors. However the precise
mechanisms by which they contribute to the pathogenesis of a focal epilepsy remain obscure, especially since
a4b2 nAChRs are known to be widely distributed within the entire brain. PET study using [18F]-F-A-85380,
a high affinity agonist at the a4b2 nAChRs, allows the determination of the regional distribution and density of
the nAChRs in healthy volunteers and in ADNFLE patients, thus offering a unique opportunity to investigate
some in vivo consequences of themolecular defect.We have assessed nAChR distribution in eight non-smoking
ADNFLE patients (from five families) bearing an identified mutation in nAChRs and in seven age-matched
non-smoking healthy volunteers using PET and [18F]-F-A-85380. Parametric images of volume of distribution
(Vd) were generated as the ratio of tissue to plasma radioactivities. The images showed a clear difference in the
pattern of the nAChR density in the brains of the patients compared to the healthy volunteers. Vd values
revealed a significant increase (between 12 and 21%, P < 0.05) in the ADNFLE patients in the mesencephalon,
the pons and the cerebellum when compared to control subjects. Statistical parametric mapping (SPM) was
then used to better analyse subtle regional differences. This analysis confirmed clear regional differences
between patients and controls: patients had increased nAChR density in the epithalamus, ventral mesence-
phalon and cerebellum, but decreased nAChR density in the right dorsolateral prefrontal region. In five patients
who underwent an additional [18F]-fluorodeoxyglucose (FDG) PET experiment, hypometabolismwas observed
in the neighbouring area of the right orbitofrontal cortex. The demonstration of a regional nAChR density
decrease in the prefrontal cortex, despite the known distribution of these receptors throughout the cerebral
cortex, is consistent with a focal epilepsy involving the frontal lobe. We also propose that the nAChR density
increase in mesencephalon is involved in the pathophysiology of ADNFLE through the role of brainstem
ascending cholinergic systems in arousal.
Keywords: ADNFLE; genetics; nicotinic receptor; PET; fluoro-A-85380
Abbreviations: ACh = acetylcholine; ADNFLE = autosomal dominant nocturnal frontal lobe epilepsy; CHRNA4 = gene coding
for the neuronal nicotinic acetylcholine receptor a4 subunit; CHRNB2 = gene coding for the neuronal nicotinic acetylcholine
receptor b2 subunit; F-A-85380 = 2-fluoro-A-85380; FDG = fluorodeoxyglucose; IPN = interpeduncular nucleus;
LDT = laterodorsal tegmental nucleus; nAChR = nicotinic acetylcholine receptor; SPM = statistical parametric mapping;
Vd = volume of distribution; VOI = volume of interest
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Introduction
Nocturnal frontal lobe epilepsy (NFLE) is a common non-
lesional focal epilepsy (Provini et al., 1999). It is sometimes
familial, with an autosomal dominant mode of inheritance
(Scheffer et al., 1995). More than a hundred families
with autosomal dominant nocturnal frontal lobe epilepsy
(ADNFLE) have been reported since the description of the
familial form (Picard and Scheffer, 2005). The pathophysio-
logical mechanisms are probably very similar in the sporadic
and the familial forms. Therefore, new insight from studies
in ADNFLE may contribute to an increased understanding of
the pathways involved in NFLE in general.
ADNFLE was the first idiopathic epilepsy in which a cau-
sative gene was found. Mutations were identified in twelve
families and in one sporadic case in the CHRNA4 and the
CHRNB2 genes coding for two different subunits (a4 and
b2) of the neuronal nicotinic acetylcholine receptor
(nAChR) (Steinlein et al., 1995; Phillips et al., 2000;
Bertrand et al., 2005; Picard and Scheffer, 2005). This finding
opened the new era of epilepsies considered as channelopa-
thies. However, the discovery of a responsible gene does not
imply a prompt understanding of the pathogenesis of the
disease. The nAChR a4 and b2 subunits are known to
assemble, classically in a 2a/3b ratio, and to form the
main brain nicotinic receptor subtype in humans. All
identified ADNFLE mutations are located within the M2
or M3 transmembrane segments lining the ionic pore of
the receptor. The mutant nAChRs have been electrophysio-
logically studied in vitro. In order to mimic the in vivo
conditions of an autosomal dominant disease, co-injection
in frog oocytes of both the normal and mutant alleles of the
mutant gene, in addition to the normal allele of the other
subunit, resulted in expression of ‘heterozygous’ mutant
receptors. In these conditions, the only common electrophy-
siological finding for six studied mutations was a significant
increase in sensitivity to acetylcholine (ACh) of the mutant
receptors (Moulard et al., 2001; Phillips et al., 2001; Bertrand
et al., 2002, 2005; Leniger et al., 2003). Another mutation, the
CHRNB2 V287L mutation, caused a retardation of channel
desensitization (De Fusco et al., 2000). Thus, contrary to the
first conclusions deduced from the assessment of ‘homozy-
gous’ mutant receptors (Weiland et al., 1996), the recent
studies suggest a gain of function of the mutant nicotinic
receptors. As an alternative common mechanism, another
study of five mutations suggested a reduction of the Ca2+
dependence of the ACh response (Rodrigues-Pinguet et al.,
2003).
Although the electrophysiological studies suggest that a
gain of function of the mutant receptors may exist in vivo,
the precise mechanisms behind the epilepsy in ADNFLE
remain unknown. The a4b2 nAChRs are widely distributed,
in particular in the thalamus and the cortex, yet their precise
distribution in the human brain is still incompletely known.
Most of these receptors are presynaptic and have a neuro-
modulatory role consisting of an enhancement of the release
of GABA, glutamate, dopamine, norepinephrine, serotonin
or ACh. Some receptors that alter the release of various
neurotransmitters are axonal at a preterminal location
(Lena et al., 1993). The presence of postsynaptic receptors
has also been demonstrated; they mediate fast excitatory
synaptic transmission (Dani, 2001). Until now, the brain
and cellular (pre-, post- or extrasynaptic) localizations of
the mutant a4b2 nAChRs directly involved in ADNFLE
pathogenesis have not been identified. Although animal
models might provide a first insight into the pathogenesis,
their results must be interpreted with caution given the
differences in brain organization and receptor distribution.
A more definitive answer might be obtained with studies of
receptor distribution in the living human brain. In vivo PET
studies may help to understand the link between the mole-
cular alteration, the cellular dysfunction and the clinical
expression.
2-[18F]-fluoro-A-85380 ([18F]-F-A-85380) is a PET
radiotracer for brain imaging of nAChRs. It has a high
affinity for heteromeric nAChRs (mainly represented by
the a4b2 receptors). Its in vivo characterization has been
performed in rodents and in monkeys (Valette et al.,
1999a, b). Its use has been validated in humans in
healthy volunteers (Kimes et al., 2003; Gallezot et al.,
2005). In the present study, we compared the regional
density of nAChRs in a group of ADNFLE patients bearing
an identified mutation with that of a group of control
subjects, after having checked in vitro that the mutations
do not change the affinity of the radioligand for the nAChRs.
Statistical parametric mapping (SPM) was used to compare
group means.
Material and methods
In vitro studies
Materials
cDNA coding for human a4, b2 and a4S248F were kindly pro-
vided by O. Steinlein (University of Munich, School of Medicine,
Institute of Human Genetics, Munich, Germany) and b2V287L
by G. Casari (San Raffaele University, Milan, Italy). (6)-[3H]-
epibatidine (55.5 Ci/mmol) was purchased from PerkinElmer
and carbamazepine from Sigma. cDNA coding for neuronal nico-
tinic receptor subunits (wild-type and mutant a4 and b2) were
transfected into human embryonal kidney (HEK 293) cells by
calcium precipitation as described previously (Chen and
Okayama, 1987). Briefly, for the wild-type receptor, cDNAs (7 mg
a4 + 7 mg b2) were transfected by calcium precipitation with care-
ful control of the pH (6.95). For the mutant receptors, different
types of transfection were made in order to simulate a ‘heterozy-
gous’ (3.5 mg a4 + 3.5 mg a4-S248F + 7 mg b2) or (7 mg a4 + 3.5 mg
b2 + 3.5 mg b2-V287L) or a ‘homozygous’ (7 mg a4-S248F + 7 mg
b2) or (7 mg a4 + 7 mg b2-V287L) mutant receptor. The cells were
placed at 37C under 5% CO2 and 20 h after transfection the
medium was changed. Then, the cells were placed for 2 days at
30C, under 5% CO2 before collection in a phosphate-buffered
saline (PBS) with 5 mM EDTA, washed twice with PBS and
finally resuspended in 3 ml/plate of this buffer for the binding
experiments.
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Competition binding assays
The affinities of epibatidine and F-A-85380 for the different a4b2
constructions were determined by equilibrium binding experiments
using [3H]-epibatidine as radioactive tracer. Cells expressing the
receptor were incubated with 0.5 nM [3H]-epibatidine and various
concentrations of competitive ligands for 2 h. The solution was
filtered through GF/C filters, previously soaked in PBS + poly-
ethyleneimine 0.5%, and the filters were washed with 6 ml of
cold PBS, dried and counted on a Rackbeta counter (PerkinElmer
LAS, Courtaboeuf, France) after the addition of 10 ml of scintilla-
tion solution (Lipoluma-PerkinElmer LAS, Courtaboeuf, France).
In equilibrium competition experiments, IC50 values were
determined by fitting the competition data by the empirical Hill
equation and converted to Ki constants using the Cheng–Prussoff
equation with Kd value [
3H]-epibatidine on human a4b2 of 20 pM.
All experiments were performed at least three times in duplicate
to ensure consistency.
Almost all the patients (6/8) were treated with carbamazepine at
the time of the study. This drug seems to act on the ionic pore of the
nAChRs as an open channel blocker (Picard et al., 1999). An addi-
tional effect on the binding site has never been excluded. Therefore,
the effect of carbamazepine on the F-A-85380/[3H]-epibatidine
binding on both wild-type and mutant receptors was evaluated
by measuring the potency of 50 mM of carbamazepine to compete
with the radiotracer and by comparing the Ki of F-A-85380 with or
without 50 mM of carbamazepine. This concentration is within the
presumed therapeutic range (20–50 mM).
Saturation binding assays using [18F]-F-A-85380
Assays were carried out at 37C in HEPES-salt solution (HSS),
containing HEPES (pH 7.4, 15 mM), 120 mM NaCl, 5.4 mM
KCl, 0.8 mM MgCl2 and 1.8 mM CaCl. Cells expressing the recep-
tor (10 ml) were incubated for 2 h in a total volume of 2 ml with
0.04 to 33 nM [18F]-F-A-85380. Non-specific binding was deter-
mined in the presence of 300 mM ()-nicotine. Incubation was
terminated by filtration through GF/B glass fibre filters, presoaked
in 1% polyethyleneimine, using a Brandel 48-channel cell harvester
(Inotech-IH-110, PerkinElmer, Courtaboeuf, France). Filters were
washed three times with 3 ml aliquots of buffer [50 mM Tris–HCl
(pH 7.4)]. Radioactivity was measured using an automatic gamma
counter (model 5000; Packard Instrument Co., Downers Grove, IL).
Binding parameters were determined from experimental data
using a non-linear least squares regression program (GraphPad
Prism). All experiments were performed at least three times in
triplicate.
In vivo studies
Subjects
Eight non-smoking Caucasian patients with ADNFLE and an
identified mutation in the nicotinic receptor (seven men; one
woman; mean age = 31 years, SD = 13.2) and seven non-smoking
age-matched healthy Caucasian volunteers (seven men; mean
age = 35 years, SD = 15.5 ; P = 0.44) were studied. All patients
were right-handed.
These patients belong to five families previously reported to
harbour mutations in the CHRNA4 (nAChR a4 subunit) gene
or the CHRNB2 (nAChR b2 subunit) gene. The patients came
from Scotland [Family D (McLellan et al., 2003)], Norway
(Steinlein et al., 2000), Italy (De Fusco et al., 2000; Gambardella
et al., 2000), Poland (Rozycka et al., 2003) and Germany (Leniger
et al., 2003). Six patients had mutations in the a4 subunit and two in
the b2 subunit. Patient characteristics, including type of mutation,
are shown in Table 1.
The usual antiepileptic medication was continued at the time
of the PET examination. Three patients were on carbamazepine
alone, three patients on carbamazepine plus clonazepam or
clobazam (of whom one demonstrated non-compliance with an
undetectable plasma level of carbamazepine, <2.5 mg/ml), one
patient on oxcarbazepine plus levetiracetam and one on clobazam
alone.
Two patients had seizures the night before the [18F]-F-A-85380
PET examination.
Study design
The study protocol for this investigation was approved by the
Medical Bioethics Committee of the Medical Centre at the
University of Paris XI and written informed consent was obtained
from all subjects.
All subjects had a MRI scan and a [18F]-F-A-85380 PET scan on
the same day. Neither patients nor controls fell asleep during the
PET examination. In addition, five of the patients had a [18F]-
fluorodeoxyglucose (FDG) PET on the following day. All PET
studies were performed using an ECAT EXACT HR+ tomograph
(Siemens Medical Solutions, Knoxville, TN, USA). This tomograph
allows simultaneous acquisition in 3D mode of 63 slices with an
isotropic intrinsic resolution of 4.5 mm.
Magnetic resonance imaging
MRI scan was performed on a 1.5 tesla signa system (General
Electric, Milwaukee, WI). A T1-weighted inversion-recovery
sequence in 3D mode and a 256 · 192 matrix over 124 slices
(1.5 mm thick) were used to generate the anatomical images.
[18F]-F-A-85380 PET imaging
A-85380 was labelled with fluorine-18 by no-carrier-added nucleo-
philic aromatic substitution (Doll et al., 1999). [18F]-F-A-85380
(188 6 24 MBq, 2–3 nmoles) was injected intravenously. The
PET acquisition started 3 h later and lasted 1 h. In five control
subjects, the PET acquisition started immediately after tracer injec-
tion and lasted 240 min with a rest period between 150 and 210 min
(Gallezot et al., 2005). A thermolabile plastic face mask ensured a
stable position of the head. Attenuation correction was performed
in each individual after segmentation of the attenuation map, using
a 68Ge transmission scan acquired for 15 min. Venous plasma
samples were drawn and unchanged radiotracer fraction was mea-
sured in the plasma using solid phase extraction. Briefly, a 500 ml
plasma sample was acidified, directly applied onto a 30 mg Oasis
MCX-SPE column and washed with 0.1 N HCl, MeOH and MeOH/
H2O/NH4OH 50/48/2 (v/v). [
18F]-F-A-85380 was eluted twice with
a MeOH/NH4OH 95/5 (v/v) solution. The radioactivity due to
unchanged [18F]-F-A-85380 in the eluted fractions was measured
in a gamma counter (Cobra Quantum D5003, PerkinElmer, Cour-
taboeuf, France) (Scho¨llhorn–Peyronneau et al., 2005).
[18F]-FDG PET imaging
[18F]-FDG was injected intravenously at a mean dose of
148 MBq. Image acquisition started with the injection and lasted
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1 h. Reconstructed images were corrected for attenuation using a
68Ge transmission scan.
PET data processing
Parametric images
The data analyses were performed using two approaches: the first is
a data-driven analysis based on volumes of interest (VOIs) drawn
on the images. Although the VOI technique is a useful method, it
only analyses selected areas; thus many brain regions may be left
unexplored. The second approach, a voxel-based analysis using the
statistical parametric mapping software (SPM2), is expected to over-
come this limitation, and the relationship between the change in
nAChR density ([18F]-F-A-85380) or in glucose metabolism
([18F]-FDG) and its anatomical basis can be investigated more
accurately.
Both data analyses were performed on volume of distribution
(Vd) parametric images based on the ratio of brain tissue to
unchanged F-A-85380 plasma concentration at equilibrium.
Parametric images were created using Anatomist software
(http://brainvisa.free.fr). For each frame collected during the last
30 min of the emission scan, the radioactivity in each voxel was
divided by the value of individually metabolite-corrected [18F]-F-A-
85380 in venous plasma at the same time, providing thus the Vd for
each voxel.
VOI analysis
For all subjects, VOIs were drawn on individual MR T1 images
using Anatomist software (http://brainvisa.free.fr). Cortical VOIs
were outlined anatomically, following the grey matter ribbon.
The identification of key sulci on individual MR images allowed
for the anatomical delineation. To ensure a good reproducibility of
the VOI placement, all VOIs were drawn by the same experienced
physician.
Fourteen VOIs were delineated in 3D on MR T1 images, based on
clearly identified anatomical structures: prefrontal (31.0 6 4.6 ml),
frontal (9.3 6 1.1 ml), operculum (3.5 6 0.5 ml), parietal (8.8 6
0.5 ml), temporal (6.9 6 1.2 ml), occipital (10.1 6 1.7 ml) cortices,
caudate nucleus (3.1 6 0.8 ml), putamen (3.9 6 0.8 ml), thalamus
(5.3 6 0.9 ml), mesencephalon (1.1 6 0.1 ml), cerebellum (5.8 6
1.4 ml), hippocampus (1.6 6 0.3 ml), pons (1.4 6 0.4 ml) and
corpus callosum (1.6 6 0.3 ml). The VOI termed ‘frontal cortex’
corresponded to a grey matter ribbon drawn from the central sulcus
on the inferior and middle frontal gyri, and included dorsolateral
prefrontal cortex, while the VOI termed ‘prefrontal cortex’ corres-
ponded to the fronto-polar area of the frontal lobe.
For each VOI, tissue to plasma ratio (Vd) was obtained from the
PET parametric images of each subject after co-registration with the
corresponding MR images using a mutual information algorithm. In
control subjects, the Vd calculated using the tissue to plasma ratios
obtained in VOIs were compared with the Vd obtained from kinetic
analysis using either a two-tissue compartmental analysis or a Logan
graphical analysis as described in Gallezot et al. (2005). The Vd
obtained in all VOIs in control subjects and patients were compared
using a two-way analysis of variance (ANOVA) followed by post-hoc
t-test using the Bonferroni correction (StatView, Abacus Concepts).
SPM analysis of PET images
SPM2 was applied to Vd parametric images to localize mean group
differences in [18F]-F-A-85380 uptake between ADNFLE patients
and controls on a voxel-by-voxel basis (Wellcome Department of
Cognitive Neurology, London, UK; implemented on Matlab 7.2).
Prior to statistical analysis, the images were spatially normalized
into an appropriate template.
For [18F]-F-A-85380 study, PET scans and MRI of each subject
were co-registered. PET images were then normalized into the MRI
template (T1.mnc) from SPM2. A smoothing procedure using an
isotropic Gaussian kernel of 8 mm in full-width at half maximum
was then applied to remove high-frequency noise from the images
and to take into account anatomical differences between subjects.
For the [18F]-FDG studies, five ADNFLE patients were compared
with a group of 30 control subjects studied at our institution (mean
age: 39 years, SD = 15). [18F]-FDG PET images were normalized
into a PET-dedicated template. The normalized images were
smoothed with a 12 mm Gaussian filter.
For both PET studies, voxel size was 2 · 2 · 2 mm. The SPM
comparisons between the parametric images of the patients and the
parametric images of the control subjects were performed using a
parametric two-sample t-test. We evaluated the entire brain volume
(>200.000 voxels). For each analysis a proportional voxel threshold
of 0.8 and proportional scaling of the parametric images were used.
We investigated differences of radiotracer concentrations at an
uncorrected P-value < 0.001 and the changes were considered
significant at a level of P < 0.05 after correction for cluster size.
In addition, the significance of some of the voxels constituting
the significant clusters was further studied by using a multiple
comparison technique.
All indicated coordinates correspond to MNI (Montreal
Neurological Institute) coordinates. When precise anatomical loca-
lization in the Co-planar Stereotaxic Atlas (Talairach and
Tournoux, 1988) was needed, the MNI coordinates of the local
maxima of each cluster were converted into Talairach coordinates
using an affine transform.
Results
In vitro studies
Competitive interactions between unlabelled and radioactive
epibatidine were studied first. The two mutations, a4-S248F
and b2-V287L, did not affect the epibatidine affinity for
human a4b2 nAChR (data not shown). Thus, identical
experimental conditions can be applied in all the competi-
tion experiments and the same epibatidine affinity constant
can be used for the binding curves. Unlabelled F-A-85380
was able to totally displace [3H]-epibatidine from wild-type
and mutant human a4b2 receptors with nearly similar
potency (see online Supplementary material, Fig. 1, left
panel). The shape of the curves indicates a binding to a single
site. The affinity constants (Ki) are reported in Table 2. The
mutations a4-S248F or b2-V287L do not modify signifi-
cantly the affinity of F-A-85380 since values are within
the 95% confidence interval (CI) of the measurements. Iden-
tical results were obtained whether the transfection simulates
a ‘heterozygous’ or a ‘homozygous’ profile (data not shown).
Saturation experiments were carried out using the radio-
tracer [18F]-F-A-85380 itself (see online Supplementary
material, Fig. 1, right panel). These experiments allowed dir-
ect measurement of the affinity constant (KD) of F-A-85380
for the receptors. KD values, reported in Table 2, are very
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close for the wild-type and both mutated receptors, confirm-
ing that mutations a4-S248F or b2-V287L do not modify
significantly the affinity of F-A-85380.
Carbamazepine (50 mM, approximately the concentration
present in the serum of patients treated for epilepsy) did not
interfere with the labelled epibatidine and did not modify the
F-A-85380 binding either to the wild-type or to the mutant
receptors (data not shown).
In vivo studies
[18F]-F-A-85380 VOI analysis
In the seven control subjects, the highest cerebral concentra-
tion of the ligand was in the thalamus. High to intermediate
levels were observed in the mesencephalon, pons, putamen,
caudate nucleus, cerebellum and cortices. The lowest con-
centration was observed in corpus callosum and occipital
cortex. In the eight ADNFLE patients, the distribution of
the concentration of ligand had a different pattern: there
was a clear increase of the radiotracer uptake in the cere-
bellum, mesencephalon and pons.
Five of our control subjects belonged to the group of
healthy volunteers reported by Gallezot et al. (2005).
These subjects underwent a long PET protocol allowing
kinetic analysis using both a two-tissue compartmental ana-
lysis and a Logan graphical analysis. In these control subjects,
the comparison between Vd calculated by using these kinetic
analyses and the Vd calculated in the present study by
using the brain tissue to unchanged F-A-85380 plasma
ratio of radioactivities at late time points (4 h after tracer
injection) revealed an excellent correlation (identity line,
r = 0.98, P < 0.0001). Therefore, the Vd values calculated
by using this ratio did reflect the receptor concentration
(Gallezot et al., 2005).
The individual parametric images in the patients con-
firmed the increased fixation in brainstem and cerebellum
(e.g. shown in Fig. 1). The comparison of Vd values
(Bonferroni corrected Student’s t-test) in the different
VOIs showed a statistically significant increase in the cere-
bellum, pons and mesencephalon (21%, P = 0.0078; 18%,
P = 0.047 and 12%, P = 0.035, respectively) in the group of
patients (Fig. 2).
Hyperfixation of [18F]-F-A-85380
detected by SPM analysis
SPM2 was used to compare the voxel values obtained in
patients and controls. Increased uptake in the group of
patients was tested at uncorrected P-values < 0.001. Among
the regions with a significant increased uptake, only those
Fig. 1 [18F]-F-A-85380 PET parametric image in one control subject (A) and in one ADNFLE patient (B).
Table 2 F-A-85380 affinity constants on wild-type and
mutant human a4b2 receptors
KD (pM) (mean 6 SD) Ki (pM) (mean 6 SD)
a4b2 267 6 84 505 6 160
a4a4 *b2 282 6 27 780 6 60
a4b2b2* 265 6 44 685 6 130
Affinity constants determined by saturation using [18F]-F-A-85380
(KD) or by competition using [
3H]-epibatidine (Ki). The star (*)
indicates a mutated subunit, S248F on a4 and V287L on b2.
Fig. 2 [18F]-F-A-85380 Vd in the different VOIs, in control subjects
(n = 7) and ADNFLE patients (n = 8). Cx = cortex; *, P < 0.05;
**, P < 0.01 (Bonferroni corrected Student’s t-test)
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providing a P corrected for the cluster level < 0.05 were kept.
The cluster size threshold allows to select regions that show
significant extent of activity. In our study, this threshold, that
depends on image characteristics, such as size and smooth-
ness, corresponded to a cluster size of 300 voxels (2.4 cm3).
A significant increase of tracer concentration in the group
of patients was observed in the region of the mesencephalon
and in the cerebellum (Table 3 and Fig. 3).
A cluster of 699 voxels appeared in the region of the
mesencephalon (P corrected < 0.001 at cluster level). The
voxel with the highest Z-score (MNI coordinates: 2 22 0;
Z = 4.63) was located above the superior colliculi, median, in
the superior area of the epithalamus, fitting best with the
region of the posterior commissure and habenula (Fig. 3). In
this cluster, a second local maximum (MNI coordinates:
0 16 16; Z = 4.25) was in the lower part of the ventral
mesencephalon, in the midline, centred on the interpedun-
cular nucleus (IPN) according to the Talairach atlas. To
identify if the local maxima within this significant cluster
were significant at the voxel level, we used P-values corrected
for multiple comparison. Multiple comparison testing was
performed with false discovery rate (FDR) technique
(Genovese et al., 2002). We did not report voxel level
P-values corrected for family-wise error (FWE), as these
values were not significant. The lack of effectiveness of
this procedure could be related to the extent of our analysis
to the entire brain and to the small number of degrees of
freedom (n = 13). The FDR-correction procedure depends
less on the extent of the space of research and applies com-
monly in SPM. The two above-mentioned local maxima
had a P-value corrected for FDR at 0.061, which is close
to significance. The probability that they corresponded to
false positives was thus very low. So the hyperfixation was
statistically significant in these voxels, which are located one
within the area of the epithalamus (habenular region), the
other within the IPN.
The second region with a significant increase was the
cerebellum, with three clusters, in the grey matter of the
lower part of both cerebellar hemispheres and in the vermis.
The voxelswith thehighestZ-scoreswere in the left hemisphere
(Z = 4.21;MNI coordinates:168052), part of a cluster of
1256 voxels, and in the right hemisphere (Z = 4.15; MNI coor-
dinates: 22 76 60), part of a cluster of 392 voxels.
In a second step, SPM analysis was applied to the data of
the subgroup of patients with an a4 mutation (n = 6) and
of the small subgroup of patients with a b2 mutation (n = 2).
The a4 subgroup showed the same pattern of increased
fixation as the whole group of ADNFLE patients, but without
significance after correction for cluster size in the mesence-
phalon (borderline significance at the voxel level for the local
maximum located in the lower part of the mesencephalon, at
2 16 14, with a PFDR-corrected = 0.050). The b2 subgroup
showed a significant increase of tracer concentration at the
cluster level in cerebellar hemispheres (Pcorrected < 0.0001). In
addition, within a small non-significant cluster appearing in
the thalami, there were two local maxima (MNI coordinates:
4 14 12 and 4 12 12) with a PFDR-corrected close to
significance (P = 0.056), located in the mediodorsal thalamic
nucleus, according to the Talairach atlas. Interestingly one of
the patients with an a4 mutation (Patient IV-6, Norway)
also showed an identical spot (MNI coordinates: 2 14 10)
with a statistically significant P at voxel level after correction
for FDR, PFDR-corrected = 0.035.
Hypofixation of [18F]-F-A-85380 detected by SPM
analysis
In the same way, SPM2 was used to localize any significant
cluster of F-A-85380 decreased binding in the group of
patients at a Puncorrected < 0.001 and a Pcorrected for the cluster
level < 0.05. The cluster size threshold allowing to select
regions with significant P-values was 200 voxels (1.6 cm3).
A cluster of 615 voxels was observed in the right prefrontal
area (Pcorrected for the cluster < 0.001). The voxel with the
highest Z-score was located in the superior frontal gyrus at
the border between Brodmann’s areas 9 and 10 (MNI coor-
dinates: 28 52 26; Z = 4.53; PFDR-corrected = 0.081) (Table 4
and Fig. 4A and B). Other significant clusters were: in the
right caudate nucleus (279 voxels; Pcorrected = 0.014; MNI
coordinates of the local maximum: 18 24 0; Z = 3.90) and
in the right rolandic opercular area (215 voxels; Pcorrected =
0.041; MNI coordinates of the local maximum: 56 4 2;
Z = 3.86).
Even at the level of individual patients, the decrease in
tracer concentration was statistically significant in the right
prefrontal region in seven patients (dorsolateral in three,
Table 3 SPM analysis of [18F]-F-A-85380 hyperfixation in ADNFLE patients
Location Local maxima MNI coordinates Z-score (voxel level) Cluster size (voxels) Pcorrected (cluster level)
x (mm) y (mm) z (mm)
Mesencephalon 2 22 0 4.63 699 < 0.001
0 16 16 4.25
Left cerebellum 16 80 52 4.21 1256 < 0.001
Right cerebellum 22 76 60 4.15 392 0.003
Cerebellar vermis 0 68 12 3.94 325 0.007
Patients n = 8; controls n = 7; Puncorrected < 0.001. Regions with a significant increase (Pcorrected at cluster level < 0.05) are shown. For each
cluster, at most three local maxima, separated by at least 8 mm, are given.
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orbitofrontal in three and both areas in one patient). A
decrease was also observed in the rolandic opercular region
(right in seven and left in one) in the eight patients, at a
significant level for three patients.
There was no difference between the patients with an a4
mutation and those with a b2 mutation.
SPM analysis of [18F]-FDG PET
FDG PET was carried out in five ADNFLE patients. The SPM
comparison was done with a group of 30 healthy volunteers.
ADNFLE patients did not show any hyperfixation when
compared to controls. A decrease of FDG fixation was
observed in the right and left anterior orbitofrontal cortex,
with a right predominance, in the right and left opercular
regions, and in the right supramarginal gyrus (inferior par-
ietal lobule) in patients (Table 5). However, for all regions,
the P-values after correction for cluster size were not statis-
tically significant.
The region of the [18F]-F-A-85380 hypofixation and the
region of glucose hypometabolism in the right prefrontal
cortex were close to each other. The glucose hypometabolism
was slightly below the region of [18F]-F-A-85380 hypofixa-
tion (Fig. 4A and D). In addition, a concomitant decrease
of [18F]-F-A-85380 fixation and glucose metabolism was
observed in almost identical parts of the right rolandic
opercular region (Fig. 4C and F).
Discussion
The comparison of [18F]-F-A-85380 binding between a
group of eight non-smoking ADNFLE patients, in whom
a mutation was identified, and a group of control subjects
showed clear regional differences. First, the comparison of
the parametric PET images between the two groups showed
statistically significant increases of tracer fixation in the cere-
bellum, pons and mesencephalon. The other VOIs showed
no significant changes. Second, SPM analysis allowed a more
discriminative spatial comparison of the entire brain. A sta-
tistically significant increase in nAChR density was observed
in the group of ADNFLE patients in a region including the
mesencephalon and an adjacent part of the diencephalon
(superior area of the epithalamus), and in the cerebellum.
Thus, both methods could identify statistically significant
changes in mesencephalon and cerebellum. The increase
in nAChR density in the brainstem is an exciting discovery
which may open new vistas on the pathogenesis of ADNFLE.
Moreover, SPM analysis allowed to identify a statistically
significant decrease in nAChR density in the right prefrontal
area in the group of ADNFLE patients. So far, it has been
hard to understand why mutations in receptors that are
present in the entire brain result in the clinical picture of
a focal epilepsy. This finding of regional decrease in nAChR
density may in part explain this phenomenon. The location
of the decrease in the prefrontal cortex appears compatible
with a frontal lobe epilepsy.
Relevance of the differences observed
between ADNFLE patients and control
subjects
The nAChR distribution in our group of control subjects
agreed with a previous study in non-smoking healthy
volunteers using the same tracer (Kimes et al., 2003). This
Fig. 3 SPM analysis of [18F]-F-A-85380 hyperfixation in ADNFLE
patients (patients n = 8; controls n = 7; Puncorrected < 0.001,
Pcorrected at cluster level < 0.05). These images focus on the
mesencephalic cluster (cluster of 699 voxels), with the blue cross
centred on the voxel with the highest Z-score (Z = 4.63; MNI
coordinates: 2 22 0). This voxel is very median, located above
the superior colliculi, in the epithalamus (region of the habenula).
The cluster extends in the ventral mesencephalon. Z-values of
statistical significance are represented by the colour bar on
the right.
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Fig. 4 SPM analysis of [18F]-F-A-85380 and of [18F]-FDG PET hypofixation in ADNFLE patients. (A–C) correspond to the [18F]-F-A-85380
analysis (patients n = 8; controls n = 7; Puncorrected < 0.001, Pcorrected at cluster level < 0.05). (D–F) correspond to the [
18F]-FDG analysis
(patients n = 5; controls n = 30; Puncorrected < 0.001). Z-values of statistical significance are represented by the colour bar on the right. The
figure focuses on the prefrontal region (B and E) with the region of glucose hypometabolism (E) being beneath the region of F-A-85380
hypofixation (B). The right side is on the right on the coronal MRI images. Parts C and F show that the regions of glucose hypometabolism
and of F-A-85380 hypofixation in the right opercular cortex are superimposable.
Table 4 SPM analysis of [18F]-F-A-85380 hypofixation in ADNFLE patients
Location Local maxima MNI coordinates Z-score (voxel level) Cluster size (voxels) Pcorrected (cluster level)
x (mm) y (mm) z (mm)
Right prefrontal cortex 28 52 26 4.53 615 < 0.001
26 66 12 4.26
18 70 6 4.26
Right caudate 18 24 0 3.90 279 0.014
26 12 18 3.85
26 24 10 3.56
Right opercular area 56 4 2 3.86 215 0.041
64 10 2 3.81
56 14 18 3.81
Patients n = 8; controls n = 7; Puncorrected < 0.001. Regions with a significant reduction (Pcorrected at cluster level < 0.05) are shown. For each
cluster, at most three local maxima, separated by at least 8 mm, are given.
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distribution was also consistent with data obtained in vitro,
except for the hippocampus which in vivo has a slightly
higher binding than the neocortex (Marutle et al., 1998).
Before interpreting the alterations of nAChR binding
observed in patients, we excluded a bias related to a
modification of affinity of the tracer for the nAChRs by
either the mutation or the antiepileptic drug carbamazepine.
The affinity of F-A-85380 was determined in vitro by two
different approaches: indirect affinity measurement (Ki) by
competition of F-A-85380 with [3H]epibatidine and direct
measurement (KD) by saturation experiments using the
radiotracer [18F]-F-A-85380 itself. Our results showed
that, despite the slight difference observed in the Ki values,
the affinity (KD) of the radiotracer [
18F]-F-A-85380 was
similar for wild-type a4b2 nAChRs and for the mutant
a4b2 nAChRs. In the literature, affinity of radioligands
for mutant nAChRs was found unchanged (Rodrigues–
Pinguet et al., 2003), slightly increased (Fonck et al.,
2005) or decreased (Kuryatov et al., 2005).
In addition, oral carbamazepine does not modify the F-A-
85380 binding to wild-type or to mutant nAChRs. Indeed,
two of our patients who did not take carbamazepine had the
same Vd values as patients taking carbamazepine. Also
in vitro, carbamazepine at a concentration in the therapeutic
range did not change the affinity of F-A-85380 for wild-type
and mutant a4b2 nAChRs.
nAChR subtype-specificity of
[18F]-F-A-85380
The increase of [18F]-F-A-85380 Vd reflects an increased
number of heteromeric nAChRs as this tracer has very
low affinity for the homomeric a7 subtypes (Deuther–
Conrad et al., 2004). Among the heteromeric nAChRs,
[18F]-F-A-85380 exhibits a clear selectivity for a4b2 over
a3b4 receptors (Ki ratio 1200) (Deuther–Conrad et al.,
2004). Affinity of our tracer for the other less abundant
subtypes (a3b2, a2b2 and a6b2) remains to be established.
Which mechanisms may give rise to a
regional increase in nAChR density?
The mechanisms behind the regional increase in nAChRs in
ADNFLE patients are yet unknown. A first possibility is that
the mutant nAChRs may have caused regional structural
CNS developmental abnormalities. The involvement of the
nAChRs in the development of the CNS has been extensively
described (Court et al., 1995; Zoli et al., 1995; Adams, 2003;
Torrao et al., 2003). The mutant receptors may possibly have
allowed the persistence of an excessive number of synapses in
the epithalamus, IPN and cerebellum.
A second possibility is a regional upregulation of recep-
tors. In rat, nicotine selectively upregulates a4b2 nAChRs,
with a different sensitivity to upregulation in different brain
regions (Nguyen et al., 2003). Even choline upregulates the
nAChRs (Sallette et al., 2005). In HEK cells expressing the
a4-S247F mutant, ACh produced an upregulation of mutant
nAChRs (Kuryatov et al., 2005). We postulate that a regional
upregulation in the habenulointerpeduncular region in
ADNFLE patients could be related to the richness in sites
of ACh release and in heteromeric nAChRs in this region
(Sastry, 1978; Tribollet et al., 2004; Zoli et al., 1998) and to
the hypersensitivity of the ADNFLE mutant nAChRs to ACh.
Could the nAChR density changes be
involved in the pathogenesis of ADNFLE?
The regional increases in nAChR density observed in the
ADNFLE patients do not seem to be caused by epileptic
seizures, since the majority of the patients did not suffer
from recent seizures at the time of examination (see
Table 1). Larger studies in the future with different popula-
tions of patients with epilepsy will determine whether the
changes in regional density are specific for the ADNFLE
syndrome. If we suppose that these changes indeed are spe-
cific, three main questions emerge. Are the regional increases
in nAChR density responsible for the sleep-related expres-
sion of the disorder? Are these modifications responsible for
epileptic seizures? And finally, are they responsible for the
particular hypermotor semiology of the seizures?
Are the nAChR density modifications responsible for the
sleep-related occurrence of the attacks?
ADNFLE seizures mainly occur during stage 2 of non-rapid
eye movement (non-REM) sleep. This stage is characterized
by the presence of sleep spindles, which are transient
Table 5 SPM analysis of [18F]-FDG PET hypofixation in ADNFLE patients
Location Local maxima MNI coordinates Z-score (voxel level) Cluster size (voxels)
x (mm) y (mm) z (mm)
Right parietal area 44 30 32 4.32 71
Right prefrontal cortex 32 50 8 3.89 329
Left prefrontal cortex 30 48 4 3.52 43
Right opercular area 66 20 4 3.40 34
64 8 16 3.38 41
Left opercular area 56 2 14 3.11 1
Patients n = 5; controls n = 30; Puncorrected < 0.001.
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physiological rhythmic oscillations, with frequencies between
11 and 15 Hz, grouped in sequences that last 0.5–3 s and
recur every 3–10 s. They originate in the thalamus and repre-
sent thalamocortical oscillations. ADNFLE seizures often
seem to arise from sleep spindles (Picard and Scheffer, 2005).
The finding of an increased number of nAChRs in the
regions of the epithalamus (medial habenular area) and of
the IPN seems particularly interesting in the context of a
sleep disorder. These structures are part of the limbic system
outflow into the brainstem (Nauta, 1958). They are linked by
the fasciculus retroflexus, a cholinergic projection from the
medial habenula to the IPN. Interestingly, this tract under-
goes an extraordinarily selective degeneration under cont-
inuous nicotine exposure in rats (Carlson et al., 2000). The
IPN projects to the ventral tegmental area and to reticular
and tegmental brainstem nuclei, particularly the laterodorsal
tegmental nucleus (LDT), which is part of the ascending
cholinergic reticular activating system, involved in arousal
regulation (Groenewegen et al., 1986; Smith et al., 1988).
This nucleus has important projections to the mediodorsal
thalamic nucleus, which projects to prefrontal cortex
(Cornwall et al., 1990).
The disruption of the fasciculus retroflexus was shown to
alter non-REM sleep duration (Haun et al., 1992). This tract
also controls the integrity of REM sleep (Valjakka et al.,
1998). Interestingly, metabolism in the IPN is not dimin-
ished in non-REM sleep as it is in other brain regions
(Kennedy et al., 1982). The IPN could be implicated in
the sleep/wake cycle primarily through its connections
with the LDT, which during non-REM sleep releases ACh
in the thalamus at the time of an arousal. This ACh release
triggers an activated awake state in thalamocortical systems
(Steriade et al., 1990; Jones, 1993; Williams et al., 1994).
Thus, an alteration affecting the IPN could result in arousal
disorders.
Could the regional modifications in
nAChR density be responsible for
epileptic seizures?
The increase in nAChR density in the group of patients
affects the habenular region, the IPN, the cerebellum and
in three patients the mediodorsal thalamic nucleus at a
statistically non-significant level. Except for the cerebellum,
we consider that these regions could be involved in patho-
genesis of seizures in ADNFLE.
The physiological richness in nAChRs of habenula and
IPN, well known in rodents, probably correlates with a
high level of sites of ACh release. In IPN, beside postsynaptic
nAChRs and presynaptic nAChRs facilitating the release of
ACh and of glutamate (Takagi, 1984; Girod and Role, 2001;
Grady et al., 2001), other nAChRs are localized at a pre-
terminal level on axons of intrinsic GABAergic neurons
(Lena et al, 1993). When ACh accumulates extrasynaptically
after periods of intense synaptic activity, these preterminal
nAChRs may be activated and then prevent prolonged
depolarizations of the postsynaptic neurons. In the presence
of hypersensitive mutant nAChRs, a low level of ACh or
choline could strongly activate postsynaptic receptors, but
be insufficient to reach the preterminal receptors, allowing
prolonged depolarizations in IPN neurons and in turn over-
activation of the LDT.
During the non-REM sleep, when the LDT nucleus, in
association with the pedunculopontine nucleus, releases
ACh in the thalamus, a tonic activation (desynchronized
awake state) is triggered and maintained in the thalamo-
cortical system. In vivo electrical stimulation of these nuclei
or local application of ACh on thalamocortical neurons
induces a depolarization of thalamocortical neurons, first
mediated by nicotinic receptors, which interrupts the sleep
spindle oscillations (Curro Dossi et al., 1991; Lee and
McCormick, 1997).
In ADNFLE, the hyperfunctioning mesopontine choliner-
gic pathway would chronically overactivate the LDT and
consequently the mediodorsal thalamic nucleus. At the
time of arousals, the release of ACh in a sensitized medio-
dorsal thalamic nucleus could prevent the normal arousal-
induced interruption of the sleep spindle oscillations and
transform them into pathological thalamocortical oscilla-
tions, triggering epileptic seizures. Such a transformation
of the sleep spindles into epileptic discharges was proposed
many years ago in absence epilepsy based on animal models,
e.g. the feline generalized penicillin epilepsy (Gloor et al.,
1979; Gloor and Fariello, 1988) and the genetic model
genetic absence epilepsy rats from Strasbourg (GAERS)
(Avanzini et al., 2000), but never in a focal epilepsy.
Could the regional modifications in nAChR density be
responsible for the particular hypermotor expression of
the seizures?
In ADNFLE, the transformation of the thalamocortical sleep
oscillations into pathological oscillations would affect the
regions of projection of the mediodorsal thalamic nucleus,
namely the orbital and dorsolateral prefrontal cortex, the
anterior cingulate cortex and the anterior part of the insula
(Behrens et al., 2003; Giguere and Goldman-Rakic, 1988).
Interestingly, the frontal sleep spindles, from which the
ADNFLE seizures seem to arise, are maximal in cortical
regions (Brodmann’s areas 9 and 10) which are reciprocally
connected to the mediodorsal thalamic nucleus (Anderer
et al., 2001).
The decrease in nAChR density and in glucose metabolism
observed in the right prefrontal cortex in the group of
patients may reflect a neuronal loss, either affecting the pre-
frontal thalamocortical neurons (presynaptic nAChRs)
which undergo an overactivation, or affecting prefrontal cor-
tical neurons (postsynaptic nAChRs) in relation to the epi-
leptic seizures. According to our results, the right rolandic
opercular region is involved in the epileptogenic thalamo-
cortical network.
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ADNFLE seizures present with intense agitation (frantic
and/or dystonic movements) evoking an innate stereotyped
motor behaviour of extrapyramidal character. Its precise
anatomical origin is not fully understood. The seizures
could trigger the release from cortical inhibitory influences
of brainstem ‘central pattern generators’ which control
innate motor behaviours essential for survival (Tassinari
et al., 2003). Such a disruption of an inhibitory connection
from prefrontal regions to the amygdala was recently sug-
gested to account for the release of archaic behaviour
suggestive of intense fear in patients with frontal lobe sei-
zures (Bartolomei et al., 2005). In our patients, the prefrontal
regions showing a decrease in nAChR density and in glucose
metabolism could be implicated in the ictal archaic motor
behaviour via a disinhibition of subcortical structures, e.g. at
a limbic or extrapyramidal level.
In summary our work shows significant regional changes
in brain nAChR density in ADNFLE patients. These changes
point towards an overactivated cholinergic pathway ascend-
ing from the brainstem. Complementary studies in humans
and in animal models are in progress and may help to sup-
port the implication of the cholinergic projections from the
brainstem to the thalamus in ADNFLE pathogenesis.
Supplementary material
Supplementary data are available at Brain Online.
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